亚盛医药-B2024年报

（於開曼群島註冊成立的有限公司）股份代號: HKEX: 6855 NASDAQ: AAPG 年 報年 報年 報年 報 202512David Sidransky202512202467202467Marc E. Lippman, MD202512 202467David SidranskyMarina S. Bozilenko20241125Debra Yu20241125Marc E. Lippman, MD202512 97927 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands FCPA, FCG, HKFCG2025225ACG (CS, CGP), HKACG (CS, CGP)2025225 FCPA, FCG, HKFCG2025225ACG (CS, CGP), HKACG (CS, CGP)2025225 68 9517B 202467202467202512Marina S. Bozilenko202512 1 20246720246720251220241125Debra Yu202512 Wilson Sonsini Goodrich & Rosati1151509 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 1617 6855AAPG ascentage.cn 2024TakedaPharmaceuticalsInternational AG®75585.77® Bcl-2lisaftoclax(APG-2575)202411NDACDE(r/r)(CLL/SLL)‘’ 20242®(FDA)T315I(CML)(-CP)III(POLARIS-2)1FAK/ALK/ROS1(TKI)APG-2449CDE(NSCLC)IIIFDA®lisaftoclax(APG-2575)APG-2449 ®lisaftoclax(APG-2575)2025 2025416 lisaftoclax(CML)(AML)(CLL)(ALL)(MDS)(MM)(Frost&Sullivan)20351,660 ®B C R - A B L1T315ICMLBCR-ABL1TKIT315I(CML)(-CP)(-AP)TKICML-CP®20251®20246T a k e d aPharmaceuticals International AG®® lisaftoclaxBcl-2202411(r/r)(CLL)(SLL)(NDA)(NMPA)(CDE)Bcl-2(BTK)Bcl-22025 (PROTACs) Bcl-2Bcl-2/Bcl-xLIAPMDM2BCR-ABL1ALKFAKEED Dana-FarberMD20241231541379 620241231 (1)NDACDE (2)CLL/SLLAMLMDSMM2 (3)NSCLC2 (4)FDA (5) ® ®®T315ICML-CPBCR-ABL1(TKI)®20251® ®2024(NCCN) CML(CSCO)CMLPh+ALL®FDACML(AML)(ALL)(GIST)(ODD)(FTD)TKICML®EMA 1FDA ® •20241231®241.020231231159.082.0052%20241231DTP734®2023123186% •202411®(TKIs)CML-CP®2022®T315I(CML)(-CP)(-AP)(TKI)CML-CP •20247®(ISAF)(TKI)T315I(CML)(-CP)(-AP)TKICML-CP •20245®2024CSCO(CML)(Ph+ ALL) •20245(NMPA)(CDE)( S D H )( G I S T )I I I(POLARIS-3) •20242FDACML-CPT315IIII(POLARIS-2)•POLARIS-1(Ph+ALL)III(POLARIS-1)•20253(NMPA)(CDE)(BTD)(Ph+ALL) •20241266(ASH)®(CP-CML)®CP-CMLTKIASH •20241121JAMA Oncology®Ib(NCT04260022)®(TKI)(CML)(Ph+ALL)CML(CML-CP)(CCyR)(MMR)61%42%TKIT315I®T315I(CP-CML) •20246®CMLPh+ALL2024(EHA 2024) •2024660(ASCO)®TKI(SDH-)(GIST)SDHGISTASCO •202442024(AACR)SDH ® •POLARIS-2POLARIS-1POLARIS-3 (Ph+ALL)III Lisaftoclax (APG-2575) LisaftoclaxBcl-2Bcl-2202411lisaftoclaxNDA(NMPA)(CDE)Bcl-2(BTK)Bcl-2lisaftoclax(CLL/SLL)(NHL)(AML)(MM)(WM)lisaftoclaxFDA(FL)(WM)(CLL)(MM)AML Lisaftoclax 2.FDA lisaftoclax •20245lisaftoclax(NMPA)(CDE)lisaftoclax(MDS)III(GLORA-4) •GLORA-3lisaftoclax(AML)III(GLORA-3)•GLORA-2lisaftoclax(BTK)CLL/SLLIII(GLORA-2)•GLORAlisaftoclaxBTKBTKCLL/SLLIII(GLORA)•lisaftoclax(MM)1b/2•lisaftoclaxAML/MDSIb/II•lisaftoclaxAML/MDSIb/II•lisaftoclaxBTKWMIb/II •20241266(ASH)lisaftoclaxLisaftoclax(r/rMM)(AL)Lisaftoclax36ORR63.9%VGPR30.6%(PFS)9.7Lisaftoclax800-1200mg(DDI)lisaftoclaxASH •2024660(ASCO)lisaftoclax(WM)Ib/IIlisaftoclaxASCOlisaftoclax(AZA)AML(r/r)(AML)Ib/II39AMLORR(CRc)64.1%51.3%10.5%(TLS)30601.3%3.9% lisaftoclax(APG-2575) •2025CLL/SLL•GLORAGLORA-2GLORA-3GLORA-4•FDAMDSIII 18A.08(3)LISAFTOCLAX(APG-2575) Alrizomadlin(APG-115) Alrizomadlin(APG-115)MDM2-p53PPIMDM2-p53p53alrizomadlin(APG-115) Alrizomadlin(APG-115)FDAAMLIIB-IVAlrizomadlin(APG-115)FDA alrizomadlin (APG-115) alrizomadlin(APG-115) •alrizomadlin(APG-115)Ib/II •alrizomadlin(APG-115)lisaftoclaxT(r/rT-PLL)(NHL)IIA•alrizomadlin(APG-115)II CDEalrizomadlin(APG-115) •alrizomadlin(APG-115)PD-1(JS001(LPS)Ib/II•alrizomadlin(APG-115)AMLMDSIb•alrizomadlin(APG-115)lisaftoclax(APG-2575)I •20247 •202442024(AACR)APG-115APG-5918(PCa)•2024320241/2APG-115(adenoid cystic carcinoma, ACC) 18A.08(3)ALRIZOMADLIN (APG-115) Pelcitoclax(APG-1252) P e l c i t o c l a x ( A P G -1252)B c l -2B c l - x L(SCLC)(NSCLC)(NET)(NHL)APG-1252FDASCLC pelcitoclax(APG-1252)Pelcitoclax(APG-1252) pelcitoclax (APG-1252) Pelcitoclax(APG-1252) pelcitoclax(APG-1252)(EGFR)NSCLCIb • •pelcitoclax(APG-1252)(NHL)Ib/II Pelcitoclax(APG-1252) APG-5918 APG-5918(EED)EED2(PRC2)APG-5918(CKD)(Hb) (FDA)IAPG-5918 APG-5918 •20241266(ASH)APG-5918T(TCLs) •202462024(EHA)APG-5918(CKD)(HB)•202442024(AACR)APG-5918MDM2alrizomadlin(APG-115)(PCa)•20231APG-5918CDE 18A.08(3)APG-5918 APG-2449 APG-2449FAKALK/ROS1TKICDEFAKPKAPG-2449APG-2449ALKTKINSCLCAPG-2449ALKTKINSCLCFAK(pFAK)APG-2449PFSpFAKALK TKI APG-2449 •202410APG-2449(NMPA)(CDE)(ALK) TKI(NSCLC)ALKNSCLCIII•APG-2449Ib/II •20241266(ASH)APG-2449(AML)APG-2449(AML)Lisaftoclax(APG-2575)•2024660(ASCO)APG-2449(NSCLC)APG-2449ASCOAPG-2449TKI2ALK TKINSCLC•202442024(AACR)APG-2449(EOC)(PLD) 18A.08(3)APG-2449 (PK/PD) ( T P D )p53-MDM220MDM2p53alrizomadlin(APG-115)p53MDM2MDM2 Bcl-xLBcl-xLBcl-xLBcl-xLBcl-xL 20232024707.0947.2 20241231541379 20241231®241.020231231159.082.052%100(HK.1801)26580020241231DTP734(HCP)®® ®2024112024(NRDL)®2022®T315I(CML)(-CP)(-AP)(TKI)CML-CP20251® 20247®(ISAF)(TKI)T315I(CML)(-CP)(-AP)TKICML-CP 2025(CACA)2024CSCO(CML)(Ph+ALL)2024(NCCN)(CML) 20212022 200,0002.52022A2024ABCGMP 20234(QualifiedPerson,QP)GMPQPGMP 2023lisaftoclax(APG-2575)®GMPFDA 50,000 2024614®®®11212%~19%202472 ® 2 0 2 462 02 0 2 461 42